Edwards Lifesciences Q4 2024 EPS $0.59 Beats Estimate; Revenue $1.39B; Generac EPS $2.80, Revenue $1.23B Misses; GE HealthCare EPS $1.45

Edwards Lifesciences Corp ($EW) reported its fourth-quarter earnings for 2024, revealing an adjusted earnings per share (EPS) of $0.59, surpassing analysts' expectations of $0.55. The company's revenue reached $1.39 billion, exceeding the estimated $1.358 billion and reflecting a 9% year-over-year growth. Notably, revenue from Transcatheter Mitral and Tricuspid Therapies grew by 88%, positioning Edwards Lifesciences for long-term expansion. For the first quarter of 2025, the company provided guidance for EPS between $0.58 and $0.64, with revenue projected between $1.35 billion and $1.43 billion. In contrast, Generac Holdings Inc. ($GNRC) also released its fourth-quarter results, reporting an adjusted EPS of $2.80, above the $2.52 estimate, and revenue of $1.23 billion, slightly below the expected $1.25 billion. This represented a 16% year-over-year revenue increase. Generac's net income was reported at $117 million, driven by a 28% growth in residential product sales. GE HealthCare Technologies ($GEHC) announced an adjusted EPS of $1.45, beating the $1.26 estimate, while its revenue of $5.32 billion fell short of the $5.33 billion forecast. The company reported a net income of $720 million, marking a 78.7% increase year-over-year. For fiscal year 2025, GE HealthCare guided for an adjusted EPS between $4.61 and $4.75.